RE: Admin Costs5 Dec 2024 17:49
Poolbeg Pharma (POLB), a clinical-stage biopharmaceutical company, announced its unaudited interim results for the six months to 30 June 2024. POLB said the value and attractiveness of POLB 001 to Pharma partners has been greatly enhanced following the independent confirmation of a potential market opportunity of c.US$10 billion as an oral preventative therapy for cancer immunotherapy-induced CRS. During the period, it also strengthened its patent and overall intellectual property portfolio with positive in vivo data. As Pharma companies seek to enhance the safety and market reach of their cancer immunotherapies, it believes that POLB 001 is well placed to generate value for shareholders while addressing a critical unmet medical need for patients.
Comment: With a strong balance sheet of £10.1m and a market opportunity of $10bn, POLB remains very well positioned to take advantage of the ongoing unmet medical need in cancer immunotherapy. Powered by AI, POLB 001 is well placed to be a company maker.